Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,769
Recruiting: 1,010
Ph III recruiting: 99
Growth YoY: −1.7%
Industry share: 19%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 35.6%
Trials / 1,000 deaths: 75 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,348)

clinicaltrialsPublishedShowing 401–406 of 406 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04502394	Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL	recruiting	Phase 1 / Phase 2	84	Kartos Therapeutics, Inc.INDUSTRY	11	Aug 4, 2022	clinicaltrials
NCT05445011	Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia	recruiting	Phase 1	12	Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER	1	Jul 6, 2022